LLY

971.94

-1.55%↓

JNJ

220.82

-1.05%↓

ABBV

202.3

-0.97%↓

UNH

367.04

-0.29%↓

AZN

181.19

-1.38%↓

LLY

971.94

-1.55%↓

JNJ

220.82

-1.05%↓

ABBV

202.3

-0.97%↓

UNH

367.04

-0.29%↓

AZN

181.19

-1.38%↓

LLY

971.94

-1.55%↓

JNJ

220.82

-1.05%↓

ABBV

202.3

-0.97%↓

UNH

367.04

-0.29%↓

AZN

181.19

-1.38%↓

LLY

971.94

-1.55%↓

JNJ

220.82

-1.05%↓

ABBV

202.3

-0.97%↓

UNH

367.04

-0.29%↓

AZN

181.19

-1.38%↓

LLY

971.94

-1.55%↓

JNJ

220.82

-1.05%↓

ABBV

202.3

-0.97%↓

UNH

367.04

-0.29%↓

AZN

181.19

-1.38%↓

Search

Guardant Health Inc

Open

BrancheGesundheitswesen

90.92 -0.33

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

89.98

Max

93.07

Schlüsselkennzahlen

By Trading Economics

Einkommen

-36M

-128M

Verkäufe

16M

281M

EPS

-0.5

Gewinnspanne

-45.684

Angestellte

2,490

EBITDA

-37M

-119M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+39.65% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.5B

12B

Vorheriger Eröffnungskurs

91.25

Vorheriger Schlusskurs

90.92

Nachrichtenstimmung

By Acuity

50%

50%

187 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Guardant Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Mai 2026, 23:41 UTC

Ergebnisse

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6. Mai 2026, 21:40 UTC

Ergebnisse

Nutrien Logs Higher Profit, Sales Growth in 1Q

6. Mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6. Mai 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6. Mai 2026, 23:13 UTC

Ergebnisse

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6. Mai 2026, 23:13 UTC

Ergebnisse

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6. Mai 2026, 23:12 UTC

Ergebnisse

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6. Mai 2026, 23:11 UTC

Ergebnisse

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6. Mai 2026, 23:07 UTC

Ergebnisse

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6. Mai 2026, 23:06 UTC

Ergebnisse

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6. Mai 2026, 23:06 UTC

Ergebnisse

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6. Mai 2026, 23:05 UTC

Ergebnisse

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6. Mai 2026, 23:04 UTC

Ergebnisse

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6. Mai 2026, 22:50 UTC

Ergebnisse

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6. Mai 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6. Mai 2026, 22:11 UTC

Ergebnisse

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6. Mai 2026, 22:11 UTC

Ergebnisse

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6. Mai 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6. Mai 2026, 21:58 UTC

Ergebnisse

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. Mai 2026, 21:47 UTC

Market Talk
Ergebnisse

Costco Posts 13% Sales Growth in April -- Market Talk

6. Mai 2026, 21:46 UTC

Ergebnisse

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6. Mai 2026, 21:40 UTC

Ergebnisse

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. Mai 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6. Mai 2026, 21:32 UTC

Heiße Aktien

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6. Mai 2026, 21:29 UTC

Ergebnisse

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Peer-Vergleich

Kursveränderung

Guardant Health Inc Prognose

Kursziel

By TipRanks

39.65% Vorteil

12-Monats-Prognose

Durchschnitt 128.83 USD  39.65%

Hoch 175 USD

Tief 85 USD

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Guardant Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

18 ratings

17

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

38.86 / 47.41Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

187 / 347 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat